Insider buying last 90 days
No open-market insider purchases were filed for EW in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every EW insider filing, plotted on the chart in Gekko.Open EW in Gekko
NYSE: EW
Edwards Lifesciences (EW) Stock Analysis & Forecast
Nov 4 close
$99.37+4.18 (+4.4%)
Gekko Brief
AI summaryNov 4 closeEdwards Lifesciences moved higher this week on a strong third-quarter 2026 report, with sales of $1.72 billion, up 11.2%, and adjusted EPS of $0.80, beating estimates by $0.06. Management raised full-year sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97-$3.05. Alongside the results, the company presented positive PROGRESS trial data supporting earlier TAVR use in patients with moderate aortic stenosis, and at least one analyst upgraded the stock from Hold to Buy with a raised price target of $113. Shares touched a 52-week high of $98.70 during the week.
The stock closed at $99.37, up 4.4%, sitting above both its 50-day ($88.48) and 200-day ($85.61) averages, with the shorter average above the longer one, confirming an established uptrend. The GekkoIndex reads 37.5, placing EW in the Distribution zone, down 11.1 points over five days. Price sits 22.2% above Gekko Fair Value of $81.34, a gap wider than the 5% threshold typically considered meaningful.
No confirmed earnings date is currently on the calendar following the 23 July report, and no insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Analyst sentiment remains favorable, with 12 of 13 firms rating the stock Buy and a consensus target of $101.87. Seasonally, the next 20 trading days have averaged a 1.8% return over 5 years, rising in 3 of them, a modest supportive signal worth noting alongside the current Distribution reading and the wide fair-value gap.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Edwards Lifesciences price vs fair value
Close $99.37200-day averageGekko Fair Value $81.34
Edwards Lifesciences quick facts
- Market cap
- $57.28B
- P/E ratio
- 55.5
- Forward P/E
- 27.2
- EPS, TTM
- $1.68
- Revenue, TTM
- $6.51B
- Profit margin
- 15.4%
- Dividend yield
- —
- Beta
- 0.83
- Volume
- 7.85M avg 4.42M
- 1-year return
- +19.6%
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±5%
- 50-day average
- $88.48
- 200-day average
- $85.61
- Next earnings
- —
- Shares outstanding
- 575.8M
Edwards Lifesciences swing-trade checklist
Edwards Lifesciences scores 2 supportive, 0 mixed and 2 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive0 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $99.37 is above the 50-day ($88.48) and 200-day ($85.61) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
37.5, Distribution
Reading 37.5 is in the Distribution zone.
See the GekkoIndex - Fair valueheadwind
22.2% above
Price is 22.2% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskno data
No data
No confirmed report date on the calendar.
See earnings - Seasonalitysupportive
+1.8% on average
From this point in the calendar, the next 20 trading days averaged +1.8% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Edwards Lifesciences stock chart and price history
Edwards Lifesciences closed at $99.37 on Nov 4, 2026, +19.6% over the past year, inside a 52-week range of $74.66 to $100.25.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +14.9%
- 3 months
- +11.3%
- 6 months
- +19.4%
- 1 year
- +19.6%
The full EW chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open EW in Gekko
Follow Edwards Lifesciences through every session
Put EW on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track EW in GekkoFree for 7 days. No credit card required.
About Edwards Lifesciences
Edwards Lifesciences develops medical devices used to treat structural heart disease and to monitor patients during surgery and intensive care. Its structural heart lineup includes transcatheter valve systems for replacing or repairing damaged heart valves through minimally invasive procedures, such as the PASCAL and Cardioband devices aimed at mitral and tricuspid valve problems, along with surgical options like the INSPIRIS aortic valve, the KONECT RESILIA tissue conduit, and the HARPOON system for mitral valve repair. On the critical care side, it makes hemodynamic monitoring equipment that tracks heart function and fluid levels, including software that warns clinicians of impending drops in blood pressure.
The company reaches hospitals and other healthcare providers through its own sales staff as well as independent distributors, and it operates across the United States, Europe, Japan and other international markets.
Edwards Lifesciences was founded in 1958 and is headquartered in Irvine, California. Its shares trade on the NYSE under the ticker EW.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- edwards.com
Edwards Lifesciences GekkoIndex: the smart money zone
Edwards Lifesciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 37.5, in the Distribution zone, down 11.1 points over five sessions.
37.5Distribution
Down 11.1 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 27 | +2.3% | +7.8% | ||
| Accumulation | 211 | +0.4% | +2.9% | ||
| Neutral | 434 | +0.1% | −1.0% | ||
| Distribution (current zone) | 24 | 0.0% | +3.7% | ||
| Selling | 1 | Too few readings yet | |||
Average EW share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the EW price, zone by zone.Track EW in Gekko
Is Edwards Lifesciences stock overvalued? Gekko Fair Value
Edwards Lifesciences trades 22.2% above Gekko Fair Value of $81.34, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Edwards Lifesciences shares are worth, recalculated every trading day.
$81.34
Gekko Fair Value, Nov 4, 2026
22.2% Overvalued
At the end of Aug 2026 the price was 10.0% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open EW in Gekko
Edwards Lifesciences insider and Congress trading
No open-market insider purchases were filed for Edwards Lifesciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in EW were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for EW, plotted on the chart in Gekko.Open EW in Gekko
Buybacks
Edwards Lifesciences has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $53.30M
- As a share of market cap
- 0.09%
- Trailing four quarters
- $772.7M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold EW.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Edwards Lifesciences earnings: next date and track record
Edwards Lifesciences beat the EPS estimate in 7 of its last 8 reports, moving 3.5% on average across the report.
7 of 8reports beat the EPS estimate
±3.5%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 23, 2026 AI summary
- What they said
- Edwards Lifesciences reported a stronger-than-expected Q2 2026 with total sales of $1.74 billion, up 12.5% year-over-year, and adjusted EPS of $0.78. Management raised full-year sales guidance: total company sales to $6.6B–$6.9B (10%–11% growth), TAVR sales to $4.75B–$5.0B (8%–9%) and TMTT guidance to $760M–$780M. Full-year adjusted EPS guidance of $2.95–$3.05 was reiterated, though the company now assumes an effective tax rate at the high end of its prior 16%–19% range due to Pillar Two and California R&D credit changes. Management highlighted broad-based strength across TAVR, mitral, tricuspid and surgical therapies, with notable momentum from PASCAL, EVOQUE and early adoption of SAPIEN M3. Key upcoming catalysts include PROGRESS trial data at TCT, a draft/final CMS NCD that could enable asymptomatic coverage and streamline access, and an expected U.S. PASCAL tricuspid approval in Q4. Management presented confident tone, emphasized long-term target of ~10% company sales growth and durable growth drivers across multiple platforms.
- Guidance
- Raised full-year sales guidance: total company sales $6.6B to $6.9B (10%–11% growth). TAVR sales $4.75B to $5.0B (8%–9%). TMTT $760M to $780M (raised from $740M–$780M). Maintained full-year adjusted EPS guidance of $2.95 to $3.05 but now assumes effective tax rate at high end of 16%–19% due to Pillar Two and California R&D credit changes.
- Risks flagged
- Higher-than-expected tax burden (Pillar Two, California R&D credit restrictions), challenging second-half 2026 comps and seasonality, dependence on regulatory outcomes (CMS NCD final memo, PROGRESS trial results, PASCAL tricuspid approval), potential adoption/behavioral hurdles for new indications (asymptomatic/moderate AS), and broader macro/healthcare uncertainties noted in forward-looking statements.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 23, 2026 | $0.78 est $0.73 | $1.74B est $1.70B | −2.1% |
| Apr 23, 2026 | $0.78 est $0.73 | $1.65B est $1.60B | +3.2% |
| Feb 10, 2026 | $0.58 est $0.62 | $1.57B est $1.55B | +3.3% |
| Oct 30, 2025 | $0.67 est $0.60 | $1.55B est $1.50B | −0.3% |
| Jul 24, 2025 | $0.67 est $0.62 | $1.53B est $1.49B | +4.0% |
| Apr 23, 2025 | $0.64 est $0.60 | $1.41B est $1.40B | +6.4% |
| Feb 11, 2025 | $0.59 est $0.55 | $1.39B est $1.36B | +6.6% |
| Oct 24, 2024 | $0.67 est $0.64 | $1.35B est $1.54B | −1.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Edwards Lifesciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Edwards Lifesciences is $101.87, +2.5% from the last close, from 13 firms rating the stock in the last 90 days.
$101.87consensus 12-month target, +2.5% from the last close
Now $99.37Avg $101.87
Low $85High $117
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 4 | Barclays | $110 | +10.7% |
| Nov 3 | Canaccord Genuity | $85 | −14.5% |
| Nov 3 | Truist Financial | $113 | +13.7% |
| Nov 3 | TD Cowen | $117 | +17.7% |
| Nov 2 | Bank of America Securities | $100 | +0.6% |
+3.7%average 20-day move after past Distribution readings
+1.8%average move over the next 20 trading days in the last 5 years
±2.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Edwards Lifesciences seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Edwards Lifesciences averaged +1.8% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.7% | 3 of 5 |
| Next 10 trading days | +2.8% | 2 of 5 |
| Next 15 trading days | +2.9% | 4 of 5 |
| Next 20 trading days | +1.8% | 3 of 5 |
| Next 30 trading days | +7.0% | 5 of 5 |
For scale, EW’s typical 20-trading-day move in either direction is about 5%.
Edwards Lifesciences market cap and key statistics
Edwards Lifesciences’s market cap is $57.28B, with a P/E ratio of 55.5 and revenue of $6.51B over the last twelve months.
Valuation
- Market cap
- $57.28B
- P/E ratio
- 55.5
- Forward P/E
- 27.2
- EPS, TTM
- $1.68
- Gekko Fair Value
- $81.34
Trading
- Volume
- 7.85M
- Avg volume, 20 days
- 4.42M
- 52-week high
- $100.25
- 52-week low
- $74.66
- Shares outstanding
- 575.8M
Financials
- Revenue, TTM
- $6.51B
- Profit margin
- 15.4%
- Return on equity
- 9.2%
- Quarterly earnings growth, YoY
- −25.4%
Risk and income
- Beta
- 0.83
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±5%
Edwards Lifesciences stock news this week
Coverage of Edwards Lifesciences this week reads positive: 7 positive, 3 neutral and 2 negative headlines.
- Edwards Lifesciences Q3 2026 Earnings Call TranscriptBenzinga, Nov 4
- Edwards Lifesciences earnings beat by $0.06, revenue topped estimatesInvesting.com, Nov 4
- Edwards Lifesciences (EW) Trial Results Put Earlier TAVR Use In FocusSimply Wall St, Nov 4
- What Do Edwards Lifesciences (NYSE:EW) Trial Results Reveal?Kalkine Media, Nov 4
- Edwards Lifesciences stock hits 52-week high at 98.7 USDInvesting.com, Nov 4
- Edwards Lifesciences stock hits 52-week high at 98.7 USD By Investing.comInvesting.com Canada, Nov 4
Edwards Lifesciences peers
Edwards Lifesciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 14.5% above |
| ABTAbbott Laboratories | Distribution | 8.0% below |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| DHRDanaher | Neutral | 3.6% above |
| MDTMedtronic | Neutral | 16.0% below |
| SYKStryker | Distribution | 6.5% above |
A peer links to its own page where one exists.
Edwards Lifesciences stock FAQ
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $57.28B at the Nov 4, 2026 close of $99.37, with 575.8M shares outstanding. The shares trade on a P/E ratio of 55.5.
What is the Edwards Lifesciences stock forecast?
The consensus analyst 12-month price target for Edwards Lifesciences is $101.87, +2.5% from the last close. Of the 13 firms that rated the stock in the last 90 days, 12 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Edwards Lifesciences stock overvalued or undervalued?
On Gekko’s estimate Edwards Lifesciences is overvalued: the Nov 4, 2026 close of $99.37 is 22.2% above Gekko Fair Value of $81.34. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
What is Edwards Lifesciences’s 52-week high and low?
Edwards Lifesciences’s 52-week high is $100.25 and its 52-week low is $74.66; it closed at $99.37 on Nov 4, 2026, +19.6% over the past year. Over the last five years the shares peaked at $131.73 on Dec 30, 2021.
Is Edwards Lifesciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (trend and seasonality) and 2 as headwinds (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Edwards Lifesciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.